Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer
Conditions
Prostate Cancer
Conditions: official terms
Prostatic Neoplasms
Conditions: Keywords
T1c, T2a, T2b
Study Type
Observational
Study Phase
N/A
Study Design
N/A
Overall Status
Recruiting
Summary
This is an observational study in which a questionnaire is used to obtain quality of life data after patients undergo a hypo-fractionated course of stereotactic body radiotherapy (SBRT) for the treatment of their prostate cancer. The SBRT itself is considered standard of care for these patients and as such, is not an official component of the study.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Male
Criteria: Inclusion Criteria:

- Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level <10 ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores are involved).

- The ability to understand and willingness to sign a written informed consent are necessary.

Exclusion Criteria:

- Patients with tumor parameters that fall outside of the inclusion criteria.

- Patients with evidence on imagining (bone scan, CT, or MRI) suggestive of disseminated disease.

- Patients who have had any form of prior prostate treatment (surgery, radiotherapy, cryotherapy, high intensity focused ultrasound, TURP).

- A prior course of hormone therapy (androgen deprivation) of greater than 3 months duration.

- The use of other concurrent investigational agents.

- There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease.

- No life expectancy restrictions will apply.

- Performance status will not be considered.
Location
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Status: Recruiting
Contact: Christopher King, MD - 310-825-9771
Start Date
January 2010
Sponsors
Jonsson Comprehensive Cancer Center
Source
Jonsson Comprehensive Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page